CA2503086A1 - Biosensor having hematocrit and oxygen biases - Google Patents
Biosensor having hematocrit and oxygen biases Download PDFInfo
- Publication number
- CA2503086A1 CA2503086A1 CA002503086A CA2503086A CA2503086A1 CA 2503086 A1 CA2503086 A1 CA 2503086A1 CA 002503086 A CA002503086 A CA 002503086A CA 2503086 A CA2503086 A CA 2503086A CA 2503086 A1 CA2503086 A1 CA 2503086A1
- Authority
- CA
- Canada
- Prior art keywords
- electrode
- biosensor strip
- metal ion
- biosensor
- working
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
- C12Q1/006—Enzyme electrodes involving specific analytes or enzymes for glucose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/004—Enzyme electrodes mediator-assisted
Abstract
A biosensor that utilizes a mediator, i.e., an isomer of phenanthroline quinone, 1,10-phenanthroline-5,6-dione, and a metal ion, such as manganese, with an enzyme dependent upon NAD(P)+, such as, for example, glucose dehydrogenase, for improving the hematocrit bias and oxygen bias of biosensors. The electrodes of the biosensors employing this mediator and a metal ion provide an accurate clinical response over a hematocrit range that ranges from about 20% to about 70% and over an oxygen tension range that ranges from about 1kPa to about 20kPa.
Description
BIOSENSOR HAVING IMPROVED HEMATOCRIT AND OXYGEN BIASES
BACKGROUND OF THE INVENTION
1. Field of the invention This invention relates to biosensors, and, more particularly, to biosensors for determining the concentration of an analyte in a biological sample.
BACKGROUND OF THE INVENTION
1. Field of the invention This invention relates to biosensors, and, more particularly, to biosensors for determining the concentration of an analyte in a biological sample.
2. Discussion of the Art All biosensors for determining the concentration of analytes in a sample of blood suffer from hematocrit sensitivity to some degree. The biosensor response decreases as the hematocrit of the sample increases. There is no 1s single reason for this decrease in the signal, though some of the reasons include diminished diffusion of the analyte in the sample and increased solution resistance. One of the methods proposed for the elimination of hematocrit sensitivity is to filter the red cells from the sample. The membrane technology to filter red cells increases both the assay time and measurement imprecision.
2o Oxygen sensitivity has presented a challenge. Biosensors employing the enzyme glucose dehydrogenase are not expected to be oxygen sensitive.
However, the oxidation-reduction reactions of the mediator (or coenzyme) could involve free radical intermediates. When these intermediates have long lifetimes, molecular oxygen can quench them, thereby rendering the chemistry 25 sensitive to oxygen tension.
U. S. Patent Nos. 5,708,247 and 5,951,836 describe a disposable glucose test strip for use in a test meter of the type that receives a disposable test strip and a sample of blood from a patient and performs an electrochemical analysis. The working formulation comprises a filler, an enzyme effective to so oxidize glucose, e.g., glucose oxidase, and a mediator effective to transfer electrons from the enzyme. The working formulation is printed over a conductive base layer to form a working electrode. The filler, for example, a silica filler, is selected to have a balance of hydrophobicity and hydrophilicity such that on drying it forms a two-dimensional network on the surface of the conductive base layer. The response of this test strip is claimed to be temperature independent over relevant temperature ranges and is substantially insensitive to the hematocrit of the patient.
In photometric biosensors, a membrane is typically used to separate red cells from a sample of whole blood. The use of a membrane increases the time of response. United States Patent No. 6,271,045 describes a photometric biosensor that employs a correction method to compensate for hematocrit 1 o sensitivity. The biosensor comprises a support member that contains a spreading layer and a reagent layer, and a capillary tube in communication with the support layer and spreading layer for transporting a sample of body fluid thereto. A capillary tube is provided on the support member whereby a fluid containing an analyte to be tested is introduced into the tube and flows through the tube to the spreading layer and contacts the reagent layer. In order to compensate for hematocrit level in the case of whole blood, additional sensors can be implemented so that they inspect the capillary tube in the test device, one sensor at the beginning of the capillary channel and one at the end. In this biosensor, whole blood is applied to the capillary channel. The entry flow of 2o whole blood is timed as it moves between sensors. The time that the blood takes to travel the length of the capillary tube is an indication of the hematocrit of the blood. That information is used to correct any shift in reflectance readings of the instrument caused by the hematocrit level. It is also known that the absorbance of hemoglobin can be measured, and the measurement can be 2s used to account for the sensitivity of the measurement to hemoglobin.
The majority of electrochemical biosensors do not use membrane technology; hence, electrochemical biosensors suffer from hematocrit sensitivity. United States Patent No. 6,284,125 describes a biosensor insensitive to hematocrit, where red cells are separated from plasma. United 3o States Patent No. 6,287,451 describes a biosensor that can employ a method in which hematocrit level can be measured electrochemically, and the corrected concentration of an analyte can be determined from the measured concentration of the analyte along with factors that depend on the sensitivity of the biosensor to hematocrit level. The magnitude of the hematocrit sensitivity is dependent on the type of biosensor and on the type of measurement. For example, if the reaction is allowed to go to completion, the lengthy reaction time s allows for complete oxidation of the analyte in the sample, thereby making the measurement less sensitive to hematocrit.
U. S. Serial No. 09/529,617, filed June 7, 2000, incorporated herein by reference, describes NAD+-dependent and NAD(P)+ -dependent enzymes having substrates of clinical value, such as glucose, D-3-hydroxybutyrate, lactate, ethanol, and cholesterol, Amperometric electrodes for detection of these substrates and other analytes can be designed by incorporating this class of enzymes and establishing electrical communication with the electrodes via the mediated oxidation of the reduced cofactors NADH and NADPH. NAD+-dependent glucose dehydrogenase can be used as the enzyme and 1, i 0-phenanthroline-5,6-dione isomer can be used as the mediator. This combination shows hematocrit sensitivity and oxygen sensitivity. The enzyme is not dependent on oxygen (oxygen does not act as a co-substrate as it does with glucose oxidase) and hence is expected to be insensitive to oxygen. However, the mediator reaction appears to be slow and hence is affected by the presence of oxygen. The mediation reaction involves free radical intermediates. If the reaction is slow, the free radical intermediates have longer half-life; hence, the probability of being quenched by molecular oxygen is high. Accordingly, the enzyme mediator combination shows oxygen dependency. The hematocrit bias of 1,10-phenanthroline-5,6-dione mediator is not clearly understood; however, it is speculated that the slow reaction rate of the mediator is responsible for significant hematocrit sensitivity. 4,7-Phenanthroline-5,6-dione does not exhibit as much sensitivity to variations in hematocrit or oxygen as does 1,10-phenanthroline-5,6-.dione. However, the structure of 1,10-phenanthroline-5,6-dione renders it easier to synthesize than does the structure of 4,7-so phenanthroline-5,6-dione. The starting materials for the synthesis of 1,10-phenanthroline-5,6-dione are much less expensive than are the starting materials for 4,7-phenanthroline-5,6-dione. Additionally, the reaction conditions for the synthesis of 1,10-phenanthroline-5,6-dione are much less severe than are the reaction conditions for 4,7-phenanthroline-5,6-dione. Accordingly, it would be desirable to reduce the sensitivity of 1,10-phenanthroline-5,6-dione to hematocrit sensitivity and oxygen sensitivity.
Glucose monitoring devices are calibrated at normal hematocrit. In samples having a lower hematocrit, the biosensor reads a higher than appropriate blood glucose level, and in samples having a higher hematocrit, the biosensor reads a lower than appropriate blood glucose level.
SUMMARY OF THE INVENTION
This invention involves a biosensor that utilizes a mediator, i.e., an isomer of phenanthroline quinone, 1,10-phenanthroline-5,6-dione, and at least one metal ion selected from the group consisting of a transition metal ion, such as, for example, manganese, iron, osmium, ruthenium, and the like, and heavier alkaline earth metal ion, such as, for example, calcium, barium, and the like, with an enzyme dependent upon NAD(P)+, such as, for example, glucose dehydrogenase, for improving the hematocrit bias and oxygen bias of the 2o biosensor. The electrodes of the biosensors employing this mediator and the foregoing metal ion provide an accurate clinical response over a hematocrit range that ranges from about 20% to about 70% and over an oxygen tension range that ranges from about 1 kPa to about 20kPa.
Although oxidation of glucose catalyzed by glucose dehydrogenase is not oxygen sensitive, the mediator can be sensitive to oxygen. The 1,10-phenanthroline-5,6-dione mediator has the structural formula:
The use of 1,10-phenanthroline-5,6-dione mediator in a glucose biosensor is described in U. S. Serial No. 09/529,617, filed June 7, 2000, incorporated herein by reference In one aspect, this invention provides a biosensor in the form of a strip, wherein the biosensor has a working electrode comprising a working ink comprising a NAD(P)+-dependent enzyme, 1,10-phenanthroline-5,6-dione as a mediator, and at least one metal ion selected from the group consisting of a transition metal ion and heavier alkaline earth metal ion. In one embodiment, 1o the biosensor contains an electrode arrangement comprising two electrodes.
The biosensor comprises: ' an electrode support;
a first electrode disposed on the electrode support, the first electrode comprising a working area, the working area comprising a working ink deposited 1 s on an electrically conductive material; and a dual-purpose reference/counter electrode disposed on the electrode support, the dual-purpose reference/counter electrode being spaced apart from the first electrode.
In another embodiment, the biosensor contains an electrode 2o arrangement comprising three electrodes. The biosensor comprises:
(a) an electrode support;
(b) a first electrode disposed on the electrode support, the first electrode being a working electrode, the working electrode comprising a working ink deposited on an electrically conductive material;
25 (c) a second electrode disposed on the electrode support, the second electrode being a reference electrode; and (d) a third electrode disposed on the electrode support, the third electrode being a counter electrode, the counter electrode comprising an electrically conductive material.
The invention described herein provides a mediator that is substantially insensitive to either hematocrit or oxygen, thereby enabling the use of this mediator in hospital and retail markets, where samples having extreme hematocrit ranges (20% to 70%) and oxygen tensions (neonatal, venous, capillary and arterial) are encountered. A biosensor in the form of a strip employing this mediator can be used for numerous analytes, such as, for example, glucose, ketone bodies, lactate, and alcohol.
The invention described herein exhibits several advantages/benefits as compared with other biosensors that are being used for similar purposes.
These advantages/benefits include:
l0 1. elimination of the requirement of a membrane or any cross-linked network;
2. the ability to employ a kinetic measurement, and consequently, the elimination of the requirement to drive the reaction to completion, thereby eliminating the hematocrit sensitivity;
2o Oxygen sensitivity has presented a challenge. Biosensors employing the enzyme glucose dehydrogenase are not expected to be oxygen sensitive.
However, the oxidation-reduction reactions of the mediator (or coenzyme) could involve free radical intermediates. When these intermediates have long lifetimes, molecular oxygen can quench them, thereby rendering the chemistry 25 sensitive to oxygen tension.
U. S. Patent Nos. 5,708,247 and 5,951,836 describe a disposable glucose test strip for use in a test meter of the type that receives a disposable test strip and a sample of blood from a patient and performs an electrochemical analysis. The working formulation comprises a filler, an enzyme effective to so oxidize glucose, e.g., glucose oxidase, and a mediator effective to transfer electrons from the enzyme. The working formulation is printed over a conductive base layer to form a working electrode. The filler, for example, a silica filler, is selected to have a balance of hydrophobicity and hydrophilicity such that on drying it forms a two-dimensional network on the surface of the conductive base layer. The response of this test strip is claimed to be temperature independent over relevant temperature ranges and is substantially insensitive to the hematocrit of the patient.
In photometric biosensors, a membrane is typically used to separate red cells from a sample of whole blood. The use of a membrane increases the time of response. United States Patent No. 6,271,045 describes a photometric biosensor that employs a correction method to compensate for hematocrit 1 o sensitivity. The biosensor comprises a support member that contains a spreading layer and a reagent layer, and a capillary tube in communication with the support layer and spreading layer for transporting a sample of body fluid thereto. A capillary tube is provided on the support member whereby a fluid containing an analyte to be tested is introduced into the tube and flows through the tube to the spreading layer and contacts the reagent layer. In order to compensate for hematocrit level in the case of whole blood, additional sensors can be implemented so that they inspect the capillary tube in the test device, one sensor at the beginning of the capillary channel and one at the end. In this biosensor, whole blood is applied to the capillary channel. The entry flow of 2o whole blood is timed as it moves between sensors. The time that the blood takes to travel the length of the capillary tube is an indication of the hematocrit of the blood. That information is used to correct any shift in reflectance readings of the instrument caused by the hematocrit level. It is also known that the absorbance of hemoglobin can be measured, and the measurement can be 2s used to account for the sensitivity of the measurement to hemoglobin.
The majority of electrochemical biosensors do not use membrane technology; hence, electrochemical biosensors suffer from hematocrit sensitivity. United States Patent No. 6,284,125 describes a biosensor insensitive to hematocrit, where red cells are separated from plasma. United 3o States Patent No. 6,287,451 describes a biosensor that can employ a method in which hematocrit level can be measured electrochemically, and the corrected concentration of an analyte can be determined from the measured concentration of the analyte along with factors that depend on the sensitivity of the biosensor to hematocrit level. The magnitude of the hematocrit sensitivity is dependent on the type of biosensor and on the type of measurement. For example, if the reaction is allowed to go to completion, the lengthy reaction time s allows for complete oxidation of the analyte in the sample, thereby making the measurement less sensitive to hematocrit.
U. S. Serial No. 09/529,617, filed June 7, 2000, incorporated herein by reference, describes NAD+-dependent and NAD(P)+ -dependent enzymes having substrates of clinical value, such as glucose, D-3-hydroxybutyrate, lactate, ethanol, and cholesterol, Amperometric electrodes for detection of these substrates and other analytes can be designed by incorporating this class of enzymes and establishing electrical communication with the electrodes via the mediated oxidation of the reduced cofactors NADH and NADPH. NAD+-dependent glucose dehydrogenase can be used as the enzyme and 1, i 0-phenanthroline-5,6-dione isomer can be used as the mediator. This combination shows hematocrit sensitivity and oxygen sensitivity. The enzyme is not dependent on oxygen (oxygen does not act as a co-substrate as it does with glucose oxidase) and hence is expected to be insensitive to oxygen. However, the mediator reaction appears to be slow and hence is affected by the presence of oxygen. The mediation reaction involves free radical intermediates. If the reaction is slow, the free radical intermediates have longer half-life; hence, the probability of being quenched by molecular oxygen is high. Accordingly, the enzyme mediator combination shows oxygen dependency. The hematocrit bias of 1,10-phenanthroline-5,6-dione mediator is not clearly understood; however, it is speculated that the slow reaction rate of the mediator is responsible for significant hematocrit sensitivity. 4,7-Phenanthroline-5,6-dione does not exhibit as much sensitivity to variations in hematocrit or oxygen as does 1,10-phenanthroline-5,6-.dione. However, the structure of 1,10-phenanthroline-5,6-dione renders it easier to synthesize than does the structure of 4,7-so phenanthroline-5,6-dione. The starting materials for the synthesis of 1,10-phenanthroline-5,6-dione are much less expensive than are the starting materials for 4,7-phenanthroline-5,6-dione. Additionally, the reaction conditions for the synthesis of 1,10-phenanthroline-5,6-dione are much less severe than are the reaction conditions for 4,7-phenanthroline-5,6-dione. Accordingly, it would be desirable to reduce the sensitivity of 1,10-phenanthroline-5,6-dione to hematocrit sensitivity and oxygen sensitivity.
Glucose monitoring devices are calibrated at normal hematocrit. In samples having a lower hematocrit, the biosensor reads a higher than appropriate blood glucose level, and in samples having a higher hematocrit, the biosensor reads a lower than appropriate blood glucose level.
SUMMARY OF THE INVENTION
This invention involves a biosensor that utilizes a mediator, i.e., an isomer of phenanthroline quinone, 1,10-phenanthroline-5,6-dione, and at least one metal ion selected from the group consisting of a transition metal ion, such as, for example, manganese, iron, osmium, ruthenium, and the like, and heavier alkaline earth metal ion, such as, for example, calcium, barium, and the like, with an enzyme dependent upon NAD(P)+, such as, for example, glucose dehydrogenase, for improving the hematocrit bias and oxygen bias of the 2o biosensor. The electrodes of the biosensors employing this mediator and the foregoing metal ion provide an accurate clinical response over a hematocrit range that ranges from about 20% to about 70% and over an oxygen tension range that ranges from about 1 kPa to about 20kPa.
Although oxidation of glucose catalyzed by glucose dehydrogenase is not oxygen sensitive, the mediator can be sensitive to oxygen. The 1,10-phenanthroline-5,6-dione mediator has the structural formula:
The use of 1,10-phenanthroline-5,6-dione mediator in a glucose biosensor is described in U. S. Serial No. 09/529,617, filed June 7, 2000, incorporated herein by reference In one aspect, this invention provides a biosensor in the form of a strip, wherein the biosensor has a working electrode comprising a working ink comprising a NAD(P)+-dependent enzyme, 1,10-phenanthroline-5,6-dione as a mediator, and at least one metal ion selected from the group consisting of a transition metal ion and heavier alkaline earth metal ion. In one embodiment, 1o the biosensor contains an electrode arrangement comprising two electrodes.
The biosensor comprises: ' an electrode support;
a first electrode disposed on the electrode support, the first electrode comprising a working area, the working area comprising a working ink deposited 1 s on an electrically conductive material; and a dual-purpose reference/counter electrode disposed on the electrode support, the dual-purpose reference/counter electrode being spaced apart from the first electrode.
In another embodiment, the biosensor contains an electrode 2o arrangement comprising three electrodes. The biosensor comprises:
(a) an electrode support;
(b) a first electrode disposed on the electrode support, the first electrode being a working electrode, the working electrode comprising a working ink deposited on an electrically conductive material;
25 (c) a second electrode disposed on the electrode support, the second electrode being a reference electrode; and (d) a third electrode disposed on the electrode support, the third electrode being a counter electrode, the counter electrode comprising an electrically conductive material.
The invention described herein provides a mediator that is substantially insensitive to either hematocrit or oxygen, thereby enabling the use of this mediator in hospital and retail markets, where samples having extreme hematocrit ranges (20% to 70%) and oxygen tensions (neonatal, venous, capillary and arterial) are encountered. A biosensor in the form of a strip employing this mediator can be used for numerous analytes, such as, for example, glucose, ketone bodies, lactate, and alcohol.
The invention described herein exhibits several advantages/benefits as compared with other biosensors that are being used for similar purposes.
These advantages/benefits include:
l0 1. elimination of the requirement of a membrane or any cross-linked network;
2. the ability to employ a kinetic measurement, and consequently, the elimination of the requirement to drive the reaction to completion, thereby eliminating the hematocrit sensitivity;
3. the selection of an appropriate reagent combination -enzyme/mediator/metal or enzyme/metal complex of the mediator - is responsible for lower hematocrit sensitivity;
4. the catalytic and electrochemical activity of the mediator/metal combination or metal complex of the mediator is responsible for oxygen 2o and hematocrit insensitivity.
5, improved performance is related to the choice of the combination of mediator and metal ion.
BRIEF DESCRIPTION OF THE DRAWINGS
F1G. 1 is a schematic diagram that illustrates a perspective view of a biosensor strip having a working electrode and a dual-purpose reference/counter electrode.
so FIG. 2 is a schematic diagram that illustrates a perspective view of a biosensor strip having a working electrode, a reference electrode, and a counter electrode.
BRIEF DESCRIPTION OF THE DRAWINGS
F1G. 1 is a schematic diagram that illustrates a perspective view of a biosensor strip having a working electrode and a dual-purpose reference/counter electrode.
so FIG. 2 is a schematic diagram that illustrates a perspective view of a biosensor strip having a working electrode, a reference electrode, and a counter electrode.
FIG. 3 is a graph showing electrochemical properties of 1,10-phenanthroline-5,6-dione in the absence of manganese chloride (Curve 1) and in the presence of manganese chloride (Curve 2).
FIG. 4 is a graph showing the response of a biosensor as a function of the concentration of glucose for three formulations involving the mediator.
FIG. 5 is a graph showing the relative signals of biosensors for of glucose (15 mM sample) as a function of hematocrit for three formulations involving the mediator. The data are normalized to the signal at 40% hematocrit.
FIG. 6 is a graph showing the relative oxygen sensitivities of biosensors io for three formulations involving the mediator. The data are normalized to 7kPa.
DETAILED DESCRIPTION
As used herein, the expression "transition metal" means those elements of a metallic nature that have partially filled d or f shells in any of their commonly occurring oxidation states. The expression " heavier alkaline earth metals"
means those elements of a metallic nature that are in the IIA column of the periodic table and that have an atomic number equal to or higher than 20.
The structural formula of the mediator 1,10-phenanthroline-5, 6-dione is shown below:
When the mediator is reduced by the enzyme, dimers or oligomers or both are formed on account of intermolecular hydrogen bonding between reduced 1,10-phenanthroline-5,6-dione molecules. These oligomers are not soluble in the reaction medium and hence are not readily regenerated for continued mediation. Intermolecular hydrogen bonding of a dimer of reduced 1,10-phenanthroline-5,6-dione is shown below.
The dimerization or oligomerization can be minimized in several ways. The nitrogen atoms can be blocked by chemical modification. A substituent, e.g., an 1o alkyl group, can be added to one or both of the nitrogen atoms in order to prevent the formation of hydrogen bonds. Preventing the formation of hydrogen bonds also increases the solubility of the mediator in both the oxidized and reduced form. The methyl derivative of 1,10-phenanthroline-5,6-dione shows increased solubility. The compound mediates the oxidation of NADH in the biosensor strip, as described in U. S. Serial No. 09/529,617, filed June 7, 2000, incorporated herein by reference. The following structural formula illustrates mono-alkylated 1,10-phenanthroline-5,6-dione, where R represents an alkyl group, such as, for example, -CH3 and X represents an anion such as BF4 X R
Synthesis of alkylated compounds requires several steps. The alkyl group is introduced after the 1,10-phenanthroline-5,6-dione is formed. The oxidation-reduction properties of alkylated 1,10-phenanthroline-5,6-dione may not be dependent on metal ion concentration, which would indicate that the alkylation process has inhibited the formation of intermolecular hydrogen bonds.
The nitrogen atoms can also be blocked by the formation of a complex having a coordination bond between a ligand and a metal ion. Complexes can be formed prior to being used in a formulation in the strip; alternatively, metal ions can simply be mixed with the ink formulation that contains the mediator.
The metal ions preferred for this invention include, but are not limited to, manganese, zinc, calcium, iron, ruthenium, cobalt, osmium, nickel, copper, rhenium, rhodium, iridium, chromium, technetium, barium, strontium. The 1o binding efficiencies in these complexes are dependent on the particular metal ion employed. For example, Mn (II) ions provide stronger binding than do Mg (II) ions. A metal complex of 1,10-phenanthroline-5,6-dione is shown below.
The generic formula of the complex cation is shown below. The ligands a, b, c, and d can represent two 1,10-phenanthroline-5,6-dione molecules or other monodentate ligands , such as, for example, chloride, water, ammonia, or the like, or multidentate ligands, such as, for example, bipyridyl or the like.
FIG. 4 is a graph showing the response of a biosensor as a function of the concentration of glucose for three formulations involving the mediator.
FIG. 5 is a graph showing the relative signals of biosensors for of glucose (15 mM sample) as a function of hematocrit for three formulations involving the mediator. The data are normalized to the signal at 40% hematocrit.
FIG. 6 is a graph showing the relative oxygen sensitivities of biosensors io for three formulations involving the mediator. The data are normalized to 7kPa.
DETAILED DESCRIPTION
As used herein, the expression "transition metal" means those elements of a metallic nature that have partially filled d or f shells in any of their commonly occurring oxidation states. The expression " heavier alkaline earth metals"
means those elements of a metallic nature that are in the IIA column of the periodic table and that have an atomic number equal to or higher than 20.
The structural formula of the mediator 1,10-phenanthroline-5, 6-dione is shown below:
When the mediator is reduced by the enzyme, dimers or oligomers or both are formed on account of intermolecular hydrogen bonding between reduced 1,10-phenanthroline-5,6-dione molecules. These oligomers are not soluble in the reaction medium and hence are not readily regenerated for continued mediation. Intermolecular hydrogen bonding of a dimer of reduced 1,10-phenanthroline-5,6-dione is shown below.
The dimerization or oligomerization can be minimized in several ways. The nitrogen atoms can be blocked by chemical modification. A substituent, e.g., an 1o alkyl group, can be added to one or both of the nitrogen atoms in order to prevent the formation of hydrogen bonds. Preventing the formation of hydrogen bonds also increases the solubility of the mediator in both the oxidized and reduced form. The methyl derivative of 1,10-phenanthroline-5,6-dione shows increased solubility. The compound mediates the oxidation of NADH in the biosensor strip, as described in U. S. Serial No. 09/529,617, filed June 7, 2000, incorporated herein by reference. The following structural formula illustrates mono-alkylated 1,10-phenanthroline-5,6-dione, where R represents an alkyl group, such as, for example, -CH3 and X represents an anion such as BF4 X R
Synthesis of alkylated compounds requires several steps. The alkyl group is introduced after the 1,10-phenanthroline-5,6-dione is formed. The oxidation-reduction properties of alkylated 1,10-phenanthroline-5,6-dione may not be dependent on metal ion concentration, which would indicate that the alkylation process has inhibited the formation of intermolecular hydrogen bonds.
The nitrogen atoms can also be blocked by the formation of a complex having a coordination bond between a ligand and a metal ion. Complexes can be formed prior to being used in a formulation in the strip; alternatively, metal ions can simply be mixed with the ink formulation that contains the mediator.
The metal ions preferred for this invention include, but are not limited to, manganese, zinc, calcium, iron, ruthenium, cobalt, osmium, nickel, copper, rhenium, rhodium, iridium, chromium, technetium, barium, strontium. The 1o binding efficiencies in these complexes are dependent on the particular metal ion employed. For example, Mn (II) ions provide stronger binding than do Mg (II) ions. A metal complex of 1,10-phenanthroline-5,6-dione is shown below.
The generic formula of the complex cation is shown below. The ligands a, b, c, and d can represent two 1,10-phenanthroline-5,6-dione molecules or other monodentate ligands , such as, for example, chloride, water, ammonia, or the like, or multidentate ligands, such as, for example, bipyridyl or the like.
-N
aw ~ 2+---N
b~j~d c A biosensor strips suitable for this invention are illustrated in FIGS. 1 and 2. Referring to FIG 1, a biosensor strip 10 comprises an electrode support 12, preferably an elongated strip of polymeric material (e.g., polyvinyl chloride, polycarbonate, polyester, or the like) supports three tracks 14a, 14b, and 14c of electrically conductive ink, preferably comprising carbon. These tracks 14a, 14b, and 14c determine the positions of electrical contacts 16a, 16b, and 16c, a io dual-purpose reference/counter electrode 18, a working electrode 20, and a trigger electrode 22. The electrical contacts 16a, 16b, and 16c can be inserted into an appropriate measurement device (not shown) for measurement of current. , Each of the elongated portions of the conductive tracks 14a, 14b, and 14c can optionally be overlaid with a track 24a, 24b, and 24c of conductive material, preferably made of a mixture comprising silver particles and silver chloride particles. The enlarged exposed area 25 of track 24b overlies the dual-purpose reference/counter electrode 18. A layer of a hydrophobic electrically insulating material 26 further overlies the tracks 14a, 14b, and 14c. The 2o positions of the dual-purpose reference/counter electrode 18, the working electrode 20, the trigger electrode 22, and the electrical contacts 16a, 16b, and 16c are not covered by the layer of hydrophobic electrically insulating material 26. This hydrophobic electrically insulating material 26 serves to prevent short circuits. Because this insulating material is hydrophobic, it can cause the sample to be restricted to the exposed electrodes. A preferred insulating material is commercially available as "POLYPLAST" (Sericol Ltd., Broadstairs, Kent, UK).
Optionally, a first layer of mesh 28, a second insulating layer 30, a second layer of mesh 32, a third insulating layer 34, and a tape 36 can overlay the hydrophobic insulating material. The tape 36 includes a small aperture 38 to allow access of the applied sample to the underlying layers of mesh 28 and 32. The second insulating layer 30 and the third insulating layer 34 include openings to allow access of the applied sample to the underlying layers of mesh 28 and 32.
The working electrode 20 comprises a layer of conductive material containing a working area 20a. The working area 20a is formed from a working 1o ink, which is printed on the layer of conductive material of the working electrode 20. The working ink comprises a mixture of an oxidation-reduction mediator, a metal ion, an enzyme, and, optionally, a conductive material.
The working area 20a is formed from a printing ink that includes a mixture of an enzyme, an oxidation-reduction mediator, a metal ion, and, is optionally, a conductive material. Alternatively, instead of an enzyme, the working area 20a can contain a substrate that is catalytically reactive with an enzyme to be assayed. The respective printing inks are applied to the working electrode 20 and the dual-purpose reference/counter electrode 18 as discrete areas of fixed length. In a preferred embodiment, the conductive material 2o comprises particles of carbon and the oxidation-reduction mediator comprises 1,10-phenanthroline-5,6-dione.
A printing ink comprises an apueous suspension of the conductive material, a redox mediator, and a metal ion. For the working electrode 20, the printing ink also includes an enzyme. For example, when the analyte to be 25 measured is glucose in ;blood, the enzyme is preferably glucose dehydrogenase, and the redox mediator is preferably a 1,10-phenanthroline-5,6-dione. In the alternative, for the working electrode 20, the printing ink can include a substrate in lieu of an enzyme when the analyte to be measured is an enzyme.
so The printing inks can be screen-printed. The printing inks can further include a polysaccharide (e.g., a guar gum or an alginate), a hydrolyzed gelatin, an enzyme stabilizer (e.g., glutamate or trehalose), a film-forming polymer (e.g., a polyvinyl alcohol), a conductive filler (e.g., carbon), a defoaming agent, a buffer, or a combination of the foregoing.
The electrodes cannot be spaced so far apart that both the working electrode 20 and the dual-purpose reference/counter electrode 18 cannot be s covered by the sample. It is preferred that the length of the path to be traversed by the sample (i.e., the sample path) be kept as short as possible in order to minimize the volume of sample required. The maximum length of the sample path can be as great as the length of the biosensor strip. However, the corresponding increase in resistance of the sample limits the length of the 1o sample path to a distance that allows the necessary response current to be generated. The resistance of the sample is also influenced by the distance from the edge of the area of the dual-purpose reference/counter electrode 18 to the edge of the working area of the working electrode 20. Reducing this distance by positioning the dual-purpose reference/counter electrode 18 downstream 15 from the working electrode 20 increases the resistance of the sample.
Positioning the electrodes contiguously is conventional.
The trigger electrode 22 can be placed downstream of the reference electrode. The trigger electrode 22 can be used to determine when the sample has been applied to the strip, thereby activating the assay protocol. See U.
S.
2o Serial No. 09!529,617, filed June 7, 2000, incorporated herein by reference.
A biosensor strip 110 suitable for this invention is illustrated in FIG. 2.
Referring to FIG. 2, an electrode support 111, preferably an elongated strip of polymeric material (e.g., polyvinyl chloride, polycarbonate, polyester, or the like) supports three tracks 112a, 112b, and 112c of electrically conductive ink, 25 preferably comprising carbon. These tracks 112a, 112b, and 112c determine the positions of electrical contacts 114a, 114b, and 114c, a reference electrode 116, a working electrode 118, and a counter electrode 120. The electrical contacts 114a, 114b, and 114c are insertable into an appropriate measurement device (not shown) for measurement of current.
3o Each of the elongated portions of the conductive tracks 112a, 112b, and 112c can optionally be overlaid with a track 122a, 122b,and 122c of conductive material, preferably made of a mixture comprising silver particles and silver chloride particles. The enlarged exposed area of track 122b overlies the reference electrode 116. A layer of a hydrophobic electrically insulating material 124 further overlies the tracks 112a, 1 l2b,and 112c. The positions of the reference electrode 116, the working electrode 118, the counter electrode 120, s and the electrical contacts 114a, 114b, and 114c are not covered by the layer of hydrophobic electrically insulating material 124. This hydrophobic electrically insulating material 124 serves to prevent short circuits. The layer of hydrophobic electrically insulating material 124 has an opening 126 formed therein. This opening 126 provides the boundary for the reaction zone of the 1o biosensor strip 110. Because this insulating material is hydrophobic, it can cause the sample to be restricted to the portions of the electrodes in the reaction zone. The working electrode 118 comprises a layer of a non-reactive electrically conductive material on which is deposited a layer 128 containing a working ink for carrying out an oxidation-reduction reaction. At least one layer 15 Of mesh 130 overlies the electrodes. This layer of mesh 130 protects the printed components from physical damage. The layer of mesh 130 also helps the sample to wet the electrodes by reducing the surface tension of the sample, thereby allowing it to spread evenly over the electrodes. A cover 132 encloses the surfaces of the electrodes that are not in contact with the electrode support 20 111. This cover 132 is a liquid impermeable membrane. The cover 132 includes a small aperture 134 to allow access of the applied sample to the underlying layer of mesh 130.
The layer of working ink 128 is deposited on that portion of the electrically conductive material of the working electrode 118 where the oxidation-reduction 25 reaction is to take place when a sample is introduced to the biosensor strip 110.
The layer of the working ink 128 can be applied to the working electrode 118 as a discrete area having a fixed length. Typical analytes of interest include, for example, glucose and ketone bodies. Typical non-reactive electrically conductive materials include, for example, carbon, platinum, palladium, and so gold. A semiconducting material such as indium doped tin oxide can be used as the non-reactive electrically conductive material. In preferred embodiments, the working ink comprises a mixture of an oxidation-reduction mediator and an enzyme. Alternatively, instead ofi an enzyme, the working ink can contain a substrate that is catalytically reactive with an enzyme to be assayed. In the biosensor strips of this invention, the reagents) are preferably applied in the form of ink containing particulate material and having binder(s), and, s accordingly, does not dissolve rapidly when subjected to the sample. In view of this feature, the oxidation-reduction reaction will occur at the interface of working electrode 118 and the sample. The glucose molecules diffuse to the surface of the working electrode 118 and react with the enzyme/mediator mixture.
io In addition to being applied to the working electrode 118, a layer of the working ink can be applied to any of the other electrodes, when desired, as a discrete area having a fixed length.
Other possible biosensor strip designs include those in which the mesh layer 130 is eliminated, and the flow channel is of such dimensions that the 15 biosensor strip takes up a liquid sample by capillary attraction. See U. S.
Serial No. 10/062,313, filed February 1, 2002, incorporated herein by reference.
The mediator can be used for any NAD(P)+ dependent enzyme.
Representative examples of these enzymes are set forth in Table 1.
2o Tablel E.C. (enzyme Enzyme name classification) Number 1.1.1.1 Alcohol dehydrogenase 1.1.1.27 Lactate dehydrogenase 1.1.1.31 ~i-hydroxybutyrate dehydrogenase 1.1.1.49 Glucose - 6- phosphate dehydrogenase 1.1.1.47 Glucose dehydrogenase 1.2.1.46 Formaldehyde dehydrogenase 1.1.1.37 Malate dehydrogenase 1.1.1.209 3-hydroxysteroid dehydrogenase Other enzyme systems that can be used with the mediator include, but are not limited to, oxidases (glucose oxidase, cholesterol oxidase, lactate oxidase).
Formulations for screen-printing reagents on an electrode comprise the components set forth in Table 2 and Table 3, where % means % by weight.
Table 2 (NAD)P+ dependent enzyme (such200 to 4000 units per gram as glucose dehydrogenase) Nicotinamide adenine dinucleotide5 to 30 (NAD) 1,10-phenanthroline-5,6-dione 0.1 to 1.5 Filler (such as carbon or silica)10 to 30%
Binder (such as hydroxyethyl 0.01 to 0.5%
cellulose or guar gum or alginate) Protein stabilizer (such as 0.01 to 2 trehalose or bovine serum albumin) Metal ion 0.1 to 10%
Buffers and other electrolytes1 to 10%
Table 3 (NAD)P+ dependent enzyme (such200 to 4000 units per gram as glucose dehydrogenase) Nicotinamide adenine dinucleotide5 to 30 (NAD) Metal complex of 1,10-phenanthroline-5,6-0.1 to 1.5 dione Filler (such as carbon or silica)10 to 30%
Binder (such as hydroxyethyl 0.01 to 0.5%
cellulose or guar gum or alginate) Protein stabilizer (such as 0.01 to 15 trehalose or bovine serum albumin) Buffers and other electrolytes1 to 10%
The performance of biosensors for determining electrochemical ketone bodies can also be enhanced with the use of this chemistry. A typical io formulation for determination of ketone bodies is shown in Table 4.
Table 4 ~i-hydroxybutyrate dehydrogenase200 to 4000 units per gram Nicotinamide adenine dinucleotide5 to 30 (NAD) 1,10-phenanthroline-5,6-dione 0.1 to 1.5 Filler (such as carbon or silica)10 to 30%
Binder (such as hydroxyethyl 0.01 to 0.5%
cellulose or guar gum or alginate) Protein stabilizer (such as.trehalose0.01 to 2 or bovine serum albumin) Metal ion 0.1 to 10%
Buffers and other electrolytes1 to 10%
In general, NAD(P)+ -dependent enzymes react with substrate according to the relationship RH2 + NAD(P)~ ~ R + NAD(P)H + H+
NAD(P)H is oxidized back to NAD(P)'" by the mediator described in this 1o invention. The rate of this oxidation reaction is slower than that of other isomers (1,7-phenanthroline-5,6-dione and 4,7-phenanthroline-5,6-dione). This slow reaction rate prevents rapid regeneration of the coenzyme and hence makes it susceptible to variation in hematocrit or oxygen in the sample. The mediator will have higher probability of reacting with molecular oxygen and hence become sensitive to oxygen. The diffusion of the mediator in the sample is affected by the hematocrit variation and slow reacting mediator will be more affected by restricted mobility compared to a fast reacting mediator. The metal ions described herein allow rapid regeneration of the coenzyme and hence makes it less susceptible to variation in hematocrit or oxygen in the sample.
2o Metal ton is required for efficient mediation of NADH oxidation by 1,10-phenanthroline-5,6-dione. In solution, 1,10-phenanthroline-5,6-dione does not show any electrochemical oxidation at physiological pH conditions. In the presence of a metal ion such as manganese, the mediator shows both oxidation and reduction current. F1G. 3 shows the electrochemical properties of 1,10-phenanthroline-5,6-dione in the presence of manganese chloride (Curve 2) and in the absence of manganese chloride (Curve 1 ).
The concentration of the metal ion required for the optimal performance s of the biosensor depends on the binding constant of the metal and the 1,10-phenanthroline-5,6-dione. The efficiency of complex formation and stability of the complex is dependent on the metal ion. For example, only 10 mM
manganese chloride is sufficient to achieve the performance that is achieved by a 360 mM magnesium chloride for 30 mM of 1,10-phenanthroline-5,6-dione in 1o the formulation. Ten (10) mM manganese chloride corresponds to a ratio of one (1) metal ion to three (3) 1,10-phenanthroline-5,6-dione molecules in the formulation that forms the metal complex. The binding constant of Pb (II) with 1,10-phenanthroline-5,6-dione is greater than the binding constant of Mn (II) or Mg (Il) with 1,10-phenanthroline-5,6-dione; however, the enzyme is inactivated 15 by Pb (II). Mediation of NADH oxidation by 1,10-phenanthroline-5,6-dione in the presence of other transition metal ions and heavier alkaline earth metal ions has been demonstrated.
Transition metal ions and heavier alkaline earth metal ions can also be used as complexes for the mediation of NADH oxidation. The performance of 2o the free ion Mn (II) mixed in the formulation is identical to the performance of the complex that is formed before it is added to the ink formulation.
The hematocrit and oxygen bias of formulations containing Mn (II) are significantly improved compared to the formulations containing Mg (II). FIG. 4 shows correlation of biosensor response as a function of concentration of 25 glucose for the three mediation chemistries. FIG. 5 shows the relative signals of a 15 mM sample as a function of hematocrit normalized to the signal at 40%
hematocrit. FIG. 6 shows oxygen sensitivities of the biosensors with three chemistries normalized to 7kPa. Similar hematocrit and oxygen bias advantages are seen with the Fe (II) complex of 1,10-phenanthroline-5,6-dione.
so In other words, using a transition metal ion or a heavier alkaline earth metal ion in the formulation improves the electrochemical properties of the compound.
Some of the transition metal ions and heavier alkaline earth metal ions show improved oxygen and hematocrit sensitivities as compared with other transition metal ions and heavier alkaline earth metal ions.
The complexes were either formed prior to use in the strip or the metal ions were mixed with the ink. The metal ions used were transition metal ions s and heavier alkaline earth metal ions.
Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention, and it should be understood that this invention is not to be unduly limited to the illustrative embodiments set forth herein.
aw ~ 2+---N
b~j~d c A biosensor strips suitable for this invention are illustrated in FIGS. 1 and 2. Referring to FIG 1, a biosensor strip 10 comprises an electrode support 12, preferably an elongated strip of polymeric material (e.g., polyvinyl chloride, polycarbonate, polyester, or the like) supports three tracks 14a, 14b, and 14c of electrically conductive ink, preferably comprising carbon. These tracks 14a, 14b, and 14c determine the positions of electrical contacts 16a, 16b, and 16c, a io dual-purpose reference/counter electrode 18, a working electrode 20, and a trigger electrode 22. The electrical contacts 16a, 16b, and 16c can be inserted into an appropriate measurement device (not shown) for measurement of current. , Each of the elongated portions of the conductive tracks 14a, 14b, and 14c can optionally be overlaid with a track 24a, 24b, and 24c of conductive material, preferably made of a mixture comprising silver particles and silver chloride particles. The enlarged exposed area 25 of track 24b overlies the dual-purpose reference/counter electrode 18. A layer of a hydrophobic electrically insulating material 26 further overlies the tracks 14a, 14b, and 14c. The 2o positions of the dual-purpose reference/counter electrode 18, the working electrode 20, the trigger electrode 22, and the electrical contacts 16a, 16b, and 16c are not covered by the layer of hydrophobic electrically insulating material 26. This hydrophobic electrically insulating material 26 serves to prevent short circuits. Because this insulating material is hydrophobic, it can cause the sample to be restricted to the exposed electrodes. A preferred insulating material is commercially available as "POLYPLAST" (Sericol Ltd., Broadstairs, Kent, UK).
Optionally, a first layer of mesh 28, a second insulating layer 30, a second layer of mesh 32, a third insulating layer 34, and a tape 36 can overlay the hydrophobic insulating material. The tape 36 includes a small aperture 38 to allow access of the applied sample to the underlying layers of mesh 28 and 32. The second insulating layer 30 and the third insulating layer 34 include openings to allow access of the applied sample to the underlying layers of mesh 28 and 32.
The working electrode 20 comprises a layer of conductive material containing a working area 20a. The working area 20a is formed from a working 1o ink, which is printed on the layer of conductive material of the working electrode 20. The working ink comprises a mixture of an oxidation-reduction mediator, a metal ion, an enzyme, and, optionally, a conductive material.
The working area 20a is formed from a printing ink that includes a mixture of an enzyme, an oxidation-reduction mediator, a metal ion, and, is optionally, a conductive material. Alternatively, instead of an enzyme, the working area 20a can contain a substrate that is catalytically reactive with an enzyme to be assayed. The respective printing inks are applied to the working electrode 20 and the dual-purpose reference/counter electrode 18 as discrete areas of fixed length. In a preferred embodiment, the conductive material 2o comprises particles of carbon and the oxidation-reduction mediator comprises 1,10-phenanthroline-5,6-dione.
A printing ink comprises an apueous suspension of the conductive material, a redox mediator, and a metal ion. For the working electrode 20, the printing ink also includes an enzyme. For example, when the analyte to be 25 measured is glucose in ;blood, the enzyme is preferably glucose dehydrogenase, and the redox mediator is preferably a 1,10-phenanthroline-5,6-dione. In the alternative, for the working electrode 20, the printing ink can include a substrate in lieu of an enzyme when the analyte to be measured is an enzyme.
so The printing inks can be screen-printed. The printing inks can further include a polysaccharide (e.g., a guar gum or an alginate), a hydrolyzed gelatin, an enzyme stabilizer (e.g., glutamate or trehalose), a film-forming polymer (e.g., a polyvinyl alcohol), a conductive filler (e.g., carbon), a defoaming agent, a buffer, or a combination of the foregoing.
The electrodes cannot be spaced so far apart that both the working electrode 20 and the dual-purpose reference/counter electrode 18 cannot be s covered by the sample. It is preferred that the length of the path to be traversed by the sample (i.e., the sample path) be kept as short as possible in order to minimize the volume of sample required. The maximum length of the sample path can be as great as the length of the biosensor strip. However, the corresponding increase in resistance of the sample limits the length of the 1o sample path to a distance that allows the necessary response current to be generated. The resistance of the sample is also influenced by the distance from the edge of the area of the dual-purpose reference/counter electrode 18 to the edge of the working area of the working electrode 20. Reducing this distance by positioning the dual-purpose reference/counter electrode 18 downstream 15 from the working electrode 20 increases the resistance of the sample.
Positioning the electrodes contiguously is conventional.
The trigger electrode 22 can be placed downstream of the reference electrode. The trigger electrode 22 can be used to determine when the sample has been applied to the strip, thereby activating the assay protocol. See U.
S.
2o Serial No. 09!529,617, filed June 7, 2000, incorporated herein by reference.
A biosensor strip 110 suitable for this invention is illustrated in FIG. 2.
Referring to FIG. 2, an electrode support 111, preferably an elongated strip of polymeric material (e.g., polyvinyl chloride, polycarbonate, polyester, or the like) supports three tracks 112a, 112b, and 112c of electrically conductive ink, 25 preferably comprising carbon. These tracks 112a, 112b, and 112c determine the positions of electrical contacts 114a, 114b, and 114c, a reference electrode 116, a working electrode 118, and a counter electrode 120. The electrical contacts 114a, 114b, and 114c are insertable into an appropriate measurement device (not shown) for measurement of current.
3o Each of the elongated portions of the conductive tracks 112a, 112b, and 112c can optionally be overlaid with a track 122a, 122b,and 122c of conductive material, preferably made of a mixture comprising silver particles and silver chloride particles. The enlarged exposed area of track 122b overlies the reference electrode 116. A layer of a hydrophobic electrically insulating material 124 further overlies the tracks 112a, 1 l2b,and 112c. The positions of the reference electrode 116, the working electrode 118, the counter electrode 120, s and the electrical contacts 114a, 114b, and 114c are not covered by the layer of hydrophobic electrically insulating material 124. This hydrophobic electrically insulating material 124 serves to prevent short circuits. The layer of hydrophobic electrically insulating material 124 has an opening 126 formed therein. This opening 126 provides the boundary for the reaction zone of the 1o biosensor strip 110. Because this insulating material is hydrophobic, it can cause the sample to be restricted to the portions of the electrodes in the reaction zone. The working electrode 118 comprises a layer of a non-reactive electrically conductive material on which is deposited a layer 128 containing a working ink for carrying out an oxidation-reduction reaction. At least one layer 15 Of mesh 130 overlies the electrodes. This layer of mesh 130 protects the printed components from physical damage. The layer of mesh 130 also helps the sample to wet the electrodes by reducing the surface tension of the sample, thereby allowing it to spread evenly over the electrodes. A cover 132 encloses the surfaces of the electrodes that are not in contact with the electrode support 20 111. This cover 132 is a liquid impermeable membrane. The cover 132 includes a small aperture 134 to allow access of the applied sample to the underlying layer of mesh 130.
The layer of working ink 128 is deposited on that portion of the electrically conductive material of the working electrode 118 where the oxidation-reduction 25 reaction is to take place when a sample is introduced to the biosensor strip 110.
The layer of the working ink 128 can be applied to the working electrode 118 as a discrete area having a fixed length. Typical analytes of interest include, for example, glucose and ketone bodies. Typical non-reactive electrically conductive materials include, for example, carbon, platinum, palladium, and so gold. A semiconducting material such as indium doped tin oxide can be used as the non-reactive electrically conductive material. In preferred embodiments, the working ink comprises a mixture of an oxidation-reduction mediator and an enzyme. Alternatively, instead ofi an enzyme, the working ink can contain a substrate that is catalytically reactive with an enzyme to be assayed. In the biosensor strips of this invention, the reagents) are preferably applied in the form of ink containing particulate material and having binder(s), and, s accordingly, does not dissolve rapidly when subjected to the sample. In view of this feature, the oxidation-reduction reaction will occur at the interface of working electrode 118 and the sample. The glucose molecules diffuse to the surface of the working electrode 118 and react with the enzyme/mediator mixture.
io In addition to being applied to the working electrode 118, a layer of the working ink can be applied to any of the other electrodes, when desired, as a discrete area having a fixed length.
Other possible biosensor strip designs include those in which the mesh layer 130 is eliminated, and the flow channel is of such dimensions that the 15 biosensor strip takes up a liquid sample by capillary attraction. See U. S.
Serial No. 10/062,313, filed February 1, 2002, incorporated herein by reference.
The mediator can be used for any NAD(P)+ dependent enzyme.
Representative examples of these enzymes are set forth in Table 1.
2o Tablel E.C. (enzyme Enzyme name classification) Number 1.1.1.1 Alcohol dehydrogenase 1.1.1.27 Lactate dehydrogenase 1.1.1.31 ~i-hydroxybutyrate dehydrogenase 1.1.1.49 Glucose - 6- phosphate dehydrogenase 1.1.1.47 Glucose dehydrogenase 1.2.1.46 Formaldehyde dehydrogenase 1.1.1.37 Malate dehydrogenase 1.1.1.209 3-hydroxysteroid dehydrogenase Other enzyme systems that can be used with the mediator include, but are not limited to, oxidases (glucose oxidase, cholesterol oxidase, lactate oxidase).
Formulations for screen-printing reagents on an electrode comprise the components set forth in Table 2 and Table 3, where % means % by weight.
Table 2 (NAD)P+ dependent enzyme (such200 to 4000 units per gram as glucose dehydrogenase) Nicotinamide adenine dinucleotide5 to 30 (NAD) 1,10-phenanthroline-5,6-dione 0.1 to 1.5 Filler (such as carbon or silica)10 to 30%
Binder (such as hydroxyethyl 0.01 to 0.5%
cellulose or guar gum or alginate) Protein stabilizer (such as 0.01 to 2 trehalose or bovine serum albumin) Metal ion 0.1 to 10%
Buffers and other electrolytes1 to 10%
Table 3 (NAD)P+ dependent enzyme (such200 to 4000 units per gram as glucose dehydrogenase) Nicotinamide adenine dinucleotide5 to 30 (NAD) Metal complex of 1,10-phenanthroline-5,6-0.1 to 1.5 dione Filler (such as carbon or silica)10 to 30%
Binder (such as hydroxyethyl 0.01 to 0.5%
cellulose or guar gum or alginate) Protein stabilizer (such as 0.01 to 15 trehalose or bovine serum albumin) Buffers and other electrolytes1 to 10%
The performance of biosensors for determining electrochemical ketone bodies can also be enhanced with the use of this chemistry. A typical io formulation for determination of ketone bodies is shown in Table 4.
Table 4 ~i-hydroxybutyrate dehydrogenase200 to 4000 units per gram Nicotinamide adenine dinucleotide5 to 30 (NAD) 1,10-phenanthroline-5,6-dione 0.1 to 1.5 Filler (such as carbon or silica)10 to 30%
Binder (such as hydroxyethyl 0.01 to 0.5%
cellulose or guar gum or alginate) Protein stabilizer (such as.trehalose0.01 to 2 or bovine serum albumin) Metal ion 0.1 to 10%
Buffers and other electrolytes1 to 10%
In general, NAD(P)+ -dependent enzymes react with substrate according to the relationship RH2 + NAD(P)~ ~ R + NAD(P)H + H+
NAD(P)H is oxidized back to NAD(P)'" by the mediator described in this 1o invention. The rate of this oxidation reaction is slower than that of other isomers (1,7-phenanthroline-5,6-dione and 4,7-phenanthroline-5,6-dione). This slow reaction rate prevents rapid regeneration of the coenzyme and hence makes it susceptible to variation in hematocrit or oxygen in the sample. The mediator will have higher probability of reacting with molecular oxygen and hence become sensitive to oxygen. The diffusion of the mediator in the sample is affected by the hematocrit variation and slow reacting mediator will be more affected by restricted mobility compared to a fast reacting mediator. The metal ions described herein allow rapid regeneration of the coenzyme and hence makes it less susceptible to variation in hematocrit or oxygen in the sample.
2o Metal ton is required for efficient mediation of NADH oxidation by 1,10-phenanthroline-5,6-dione. In solution, 1,10-phenanthroline-5,6-dione does not show any electrochemical oxidation at physiological pH conditions. In the presence of a metal ion such as manganese, the mediator shows both oxidation and reduction current. F1G. 3 shows the electrochemical properties of 1,10-phenanthroline-5,6-dione in the presence of manganese chloride (Curve 2) and in the absence of manganese chloride (Curve 1 ).
The concentration of the metal ion required for the optimal performance s of the biosensor depends on the binding constant of the metal and the 1,10-phenanthroline-5,6-dione. The efficiency of complex formation and stability of the complex is dependent on the metal ion. For example, only 10 mM
manganese chloride is sufficient to achieve the performance that is achieved by a 360 mM magnesium chloride for 30 mM of 1,10-phenanthroline-5,6-dione in 1o the formulation. Ten (10) mM manganese chloride corresponds to a ratio of one (1) metal ion to three (3) 1,10-phenanthroline-5,6-dione molecules in the formulation that forms the metal complex. The binding constant of Pb (II) with 1,10-phenanthroline-5,6-dione is greater than the binding constant of Mn (II) or Mg (Il) with 1,10-phenanthroline-5,6-dione; however, the enzyme is inactivated 15 by Pb (II). Mediation of NADH oxidation by 1,10-phenanthroline-5,6-dione in the presence of other transition metal ions and heavier alkaline earth metal ions has been demonstrated.
Transition metal ions and heavier alkaline earth metal ions can also be used as complexes for the mediation of NADH oxidation. The performance of 2o the free ion Mn (II) mixed in the formulation is identical to the performance of the complex that is formed before it is added to the ink formulation.
The hematocrit and oxygen bias of formulations containing Mn (II) are significantly improved compared to the formulations containing Mg (II). FIG. 4 shows correlation of biosensor response as a function of concentration of 25 glucose for the three mediation chemistries. FIG. 5 shows the relative signals of a 15 mM sample as a function of hematocrit normalized to the signal at 40%
hematocrit. FIG. 6 shows oxygen sensitivities of the biosensors with three chemistries normalized to 7kPa. Similar hematocrit and oxygen bias advantages are seen with the Fe (II) complex of 1,10-phenanthroline-5,6-dione.
so In other words, using a transition metal ion or a heavier alkaline earth metal ion in the formulation improves the electrochemical properties of the compound.
Some of the transition metal ions and heavier alkaline earth metal ions show improved oxygen and hematocrit sensitivities as compared with other transition metal ions and heavier alkaline earth metal ions.
The complexes were either formed prior to use in the strip or the metal ions were mixed with the ink. The metal ions used were transition metal ions s and heavier alkaline earth metal ions.
Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention, and it should be understood that this invention is not to be unduly limited to the illustrative embodiments set forth herein.
Claims (34)
1. A biosensor strip comprising:
(a) an electrode support;
(b) a first electrode disposed on said electrode support, said first electrode being a working electrode, said working electrode comprising a working ink deposited on an electrically conductive material, wherein said working ink comprises an enzyme, a mediator, and at least one metal ion selected from the group consisting of a transition metal ion and heavier alkaline earth metal ion, wherein said mediator is 1,10-phenanthroline-5,6-dione or a derivative thereof;
(c) a second electrode disposed on said electrode support, said second electrode being a reference electrode; and (d) a third electrode disposed on said electrode support, said third electrode being a counter electrode, said counter electrode comprising an electrically conductive material.
(a) an electrode support;
(b) a first electrode disposed on said electrode support, said first electrode being a working electrode, said working electrode comprising a working ink deposited on an electrically conductive material, wherein said working ink comprises an enzyme, a mediator, and at least one metal ion selected from the group consisting of a transition metal ion and heavier alkaline earth metal ion, wherein said mediator is 1,10-phenanthroline-5,6-dione or a derivative thereof;
(c) a second electrode disposed on said electrode support, said second electrode being a reference electrode; and (d) a third electrode disposed on said electrode support, said third electrode being a counter electrode, said counter electrode comprising an electrically conductive material.
2. The biosensor strip of claim 1, wherein said at least one metal ion is selected from the group consisting of manganese, iron, cobalt, osmium, and ruthenium.
3. The biosensor strip of claim 1, wherein said at least one metal ion is selected from the group consisting of calcium, strontium, and barium.
4. The biosensor strip of claim 1, wherein said at least one metal ion is in the form of a salt.
5. The biosensor strip of claim 1, wherein said at least one metal ion is in the form of a complex with said mediator.
6. The biosensor strip of claim 1, wherein said enzyme is selected from the group consisting of glucose oxidase and glucose dehydrogenase.
7. The biosensor strip of claim 1, wherein said enzyme is NAD(P)+ -dependent dehydrogenase.
8. The biosensor strip of claim 1, further comprising a covering layer defining an enclosed space over said electrodes, said covering layer having an aperture for receiving a sample into said enclosed space.
9. The biosensor strip of claim 8, further comprising a least one layer of mesh interposed in the enclosed space between said covering layer and said electrodes.
10. The biosensor strip of claim 1, wherein said counter electrode is positioned relative to said working electrode and said reference electrode such that a liquid sample will contact said working electrode and said reference electrode prior to contacting said counter electrode.
11. A method for determining the concentration of an analyte in a sample of biological fluid, said method comprising the steps of:
(a) providing the biosensor strip of claim 1;
(b) inserting said biosensor strip into an analyte monitor;
(c) applying said biological fluid to said biosensor strip;
(d) applying a voltage at the working electrode with respect to the reference electrode;
(e) measuring the current flowing between the working electrode and the counter electrode; and (f) correlating the current measured to the concentration of said analyte.
(a) providing the biosensor strip of claim 1;
(b) inserting said biosensor strip into an analyte monitor;
(c) applying said biological fluid to said biosensor strip;
(d) applying a voltage at the working electrode with respect to the reference electrode;
(e) measuring the current flowing between the working electrode and the counter electrode; and (f) correlating the current measured to the concentration of said analyte.
12. A biosensor strip comprising:
(a) an electrode support;
(b) a first electrode, said first electrode being a working electrode, said working electrode comprising working ink deposited on an electrically conductive material, wherein said working ink comprises an enzyme, a mediator, and at least one metal ion selected from the group consisting of a transition metal ion and heavier alkaline earth metal ion, wherein said mediator is 1,10-phenanthroline-5,6-dione or a derivative thereof.
(c) a second electrode, said second electrode being a dual-purpose reference/counter electrode.
(a) an electrode support;
(b) a first electrode, said first electrode being a working electrode, said working electrode comprising working ink deposited on an electrically conductive material, wherein said working ink comprises an enzyme, a mediator, and at least one metal ion selected from the group consisting of a transition metal ion and heavier alkaline earth metal ion, wherein said mediator is 1,10-phenanthroline-5,6-dione or a derivative thereof.
(c) a second electrode, said second electrode being a dual-purpose reference/counter electrode.
13. The biosensor of claim 12, wherein said at Least one metal ion is selected from the group consisting of manganese, iron, cobalt, osmium, and ruthenium.
14. The biosensor of claim 12, wherein said at least one heavier alkaline earth metal ion is selected from the group consisting of calcium, strontium, and barium.
15. The biosensor strip of claim 12, wherein said at least one metal ion is in the form of a salt.
16. The biosensor strip of claim 12, wherein said at least one metal ion is in the form of a complex with said mediator.
17. The biosensor strip of claim 12, wherein said enzyme is selected from the group consisting of glucose oxidase and glucose dehydrogenase.
18. The biosensor strip of claim 12, wherein said enzyme is NAD(P)+ -dependent dehydrogenase.
19. The biosensor strip of claim 12, wherein said electrode arrangement further includes a trigger electrode.
20. A method for determining the concentration of an analyte in a sample of biological fluid, said method comprising the steps of:
(a) providing the biosensor strip of claim 12;
(b) applying said biological fluid to said biosensor strip;
(c) inserting said biosensor strip into an analyte monitor;
(d) applying a voltage at the working electrode with respect to the reference electrode;
(e) measuring the current flowing between the working electrode and the counter electrode; and (f) correlating the current measured to the concentration of said analyte.
(a) providing the biosensor strip of claim 12;
(b) applying said biological fluid to said biosensor strip;
(c) inserting said biosensor strip into an analyte monitor;
(d) applying a voltage at the working electrode with respect to the reference electrode;
(e) measuring the current flowing between the working electrode and the counter electrode; and (f) correlating the current measured to the concentration of said analyte.
21. A biosensor strip comprising:
(a) an electrode support;
(b) an electrode arrangement comprising at least two electrodes, one of said at least two electrodes being a working electrode, said working electrode disposed on said electrode support, said working electrode comprising a reaction layer comprising an enzyme, a mediator, and at least one metal ion selected from the group consisting of a transition metal ion and heavier alkaline earth metal ion, wherein said mediator is 1,10-phenanthroline-5,6-dione or a derivative thereof;
(c) another of said at least two electrodes being a counter electrode, said counter electrode disposed on said electrode support.
(a) an electrode support;
(b) an electrode arrangement comprising at least two electrodes, one of said at least two electrodes being a working electrode, said working electrode disposed on said electrode support, said working electrode comprising a reaction layer comprising an enzyme, a mediator, and at least one metal ion selected from the group consisting of a transition metal ion and heavier alkaline earth metal ion, wherein said mediator is 1,10-phenanthroline-5,6-dione or a derivative thereof;
(c) another of said at least two electrodes being a counter electrode, said counter electrode disposed on said electrode support.
22. The biosensor strip of claim 21, wherein said at least one metal ion is selected from the group consisting of manganese, iron, cobalt, osmium, and, ruthenium.
23. The biosensor strip of claim 21, wherein said at least one metal ion is selected from the group consisting of calcium, strontium, and barium.
24. The biosensor strip of claim 21, wherein said enzyme is selected from the group consisting of glucose oxidase and glucose dehydrogenase.
25. The biosensor strip of claim 21, wherein said enzyme is NAD(P)+ dependent dehydrogenase.
26. A method for determining the concentration of an analyte in a sample of biological fluid, said method comprising the steps of:
(a) providing the biosensor strip of claim 21;
(b) inserting said biosensor strip into an analyte monitor;
(c) applying said biological fluid to said biosensor strip;
(d) applying a voltage at the working electrode with respect to the reference electrode;
(e) measuring the current flowing between the working electrode and the counter electrode; and (f) correlating the current measured to the concentration of said analyte.
(a) providing the biosensor strip of claim 21;
(b) inserting said biosensor strip into an analyte monitor;
(c) applying said biological fluid to said biosensor strip;
(d) applying a voltage at the working electrode with respect to the reference electrode;
(e) measuring the current flowing between the working electrode and the counter electrode; and (f) correlating the current measured to the concentration of said analyte.
27. A biosensor strip comprising:
(a) an electrode support;
(b) an electrode arrangement comprising at least two electrodes, one of said at least two electrodes being a working electrode, said working electrode disposed on said electrode support, said working electrode comprising a reaction layer comprising an enzyme and a complex comprising a mediator and at least one metal ion selected from the group consisting of a transition metal ion and heavier alkaline earth metal ion, wherein said mediator is 1,10-phenanthroline-5,6-dione or a derivative thereof;
(c) another of said at least two electrodes being a counter electrode, said counter electrode disposed on said electrode support.
(a) an electrode support;
(b) an electrode arrangement comprising at least two electrodes, one of said at least two electrodes being a working electrode, said working electrode disposed on said electrode support, said working electrode comprising a reaction layer comprising an enzyme and a complex comprising a mediator and at least one metal ion selected from the group consisting of a transition metal ion and heavier alkaline earth metal ion, wherein said mediator is 1,10-phenanthroline-5,6-dione or a derivative thereof;
(c) another of said at least two electrodes being a counter electrode, said counter electrode disposed on said electrode support.
28. The biosensor strip of claim 27, wherein said at least one metal ion is selected from the group consisting of manganese, iron, cobalt, osmium, and ruthenium.
29. The biosensor strip of claim 27, wherein said at least one metal ion is selected from the group consisting of calcium, strontium, and barium.
30. The biosensor strip of claim 27, wherein said enzyme is selected from the group consisting of glucose oxidase and glucose dehydrogenase.
31. The biosensor strip of claim 27, wherein said enzyme is NAD(P)+ dependent dehydrogenase.
32. The biosensor strip of claim 27, wherein said electrode arrangement further includes a reference electrode.
33. The biosensor strip of claim 27, wherein said electrode arrangement further includes a trigger electrode.
34. A method for determining the concentration of an analyte in a sample of biological fluid, said method comprising the steps of:
(a) providing the biosensor strip of claim 27;
(b) inserting said biosensor strip into an analyte monitor;
(c) applying said biological fluid to said biosensor strip;
(d) applying a voltage at the working electrode with respect to the reference electrode;
(e) measuring the current flowing between the working electrode and the counter electrode; and (f) correlating the current measured to the concentration of said analyte.
(a) providing the biosensor strip of claim 27;
(b) inserting said biosensor strip into an analyte monitor;
(c) applying said biological fluid to said biosensor strip;
(d) applying a voltage at the working electrode with respect to the reference electrode;
(e) measuring the current flowing between the working electrode and the counter electrode; and (f) correlating the current measured to the concentration of said analyte.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/278,657 US7501053B2 (en) | 2002-10-23 | 2002-10-23 | Biosensor having improved hematocrit and oxygen biases |
US10/278,657 | 2002-10-23 | ||
PCT/US2003/033532 WO2004038401A2 (en) | 2002-10-23 | 2003-10-22 | Biosensor having hematocrit and oxygen biases |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2503086A1 true CA2503086A1 (en) | 2004-05-06 |
Family
ID=32106586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002503086A Abandoned CA2503086A1 (en) | 2002-10-23 | 2003-10-22 | Biosensor having hematocrit and oxygen biases |
Country Status (6)
Country | Link |
---|---|
US (4) | US7501053B2 (en) |
EP (1) | EP1556689A2 (en) |
JP (1) | JP4695879B2 (en) |
AU (1) | AU2003286597A1 (en) |
CA (1) | CA2503086A1 (en) |
WO (1) | WO2004038401A2 (en) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7501053B2 (en) * | 2002-10-23 | 2009-03-10 | Abbott Laboratories | Biosensor having improved hematocrit and oxygen biases |
AU2003290784A1 (en) * | 2002-11-15 | 2004-06-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for detecting asymmetric dimethylarginine in a biological sample |
US8210349B2 (en) * | 2003-03-25 | 2012-07-03 | Arkray, Inc. | Sensor storage container |
ES2657627T3 (en) * | 2003-06-20 | 2018-03-06 | F. Hoffmann-La Roche Ag | Electrochemical biosensors |
US20050067277A1 (en) * | 2003-09-30 | 2005-03-31 | Pierce Robin D. | Low volume electrochemical biosensor |
WO2005078118A1 (en) | 2004-02-06 | 2005-08-25 | Bayer Healthcare Llc | Oxidizable species as an internal reference for biosensors and method of use |
US7511142B2 (en) | 2004-07-28 | 2009-03-31 | Agency For Science, Technology And Research | Mediator-modified redox biomolecules for use in electrochemical determination of analyte |
US7879567B2 (en) * | 2004-10-05 | 2011-02-01 | Asahi Kasei Pharma Corporation | Method for stabilizing coenzyme and composition therefor |
US7922883B2 (en) | 2005-06-08 | 2011-04-12 | Abbott Laboratories | Biosensors and methods of using the same |
US20060281187A1 (en) | 2005-06-13 | 2006-12-14 | Rosedale Medical, Inc. | Analyte detection devices and methods with hematocrit/volume correction and feedback control |
WO2007000596A1 (en) * | 2005-06-29 | 2007-01-04 | Oxford Biosensors Limited | Electrode preconditioning |
US20070017824A1 (en) * | 2005-07-19 | 2007-01-25 | Rippeth John J | Biosensor and method of manufacture |
AU2006272909B2 (en) | 2005-07-20 | 2013-02-07 | Bayer Healthcare Llc | Gated amperometry |
WO2007041244A2 (en) | 2005-09-30 | 2007-04-12 | Intuity Medical, Inc. | Multi-site body fluid sampling and analysis cartridge |
AU2006297572B2 (en) | 2005-09-30 | 2012-11-15 | Ascensia Diabetes Care Holdings Ag | Gated Voltammetry |
US20080272006A1 (en) * | 2005-11-30 | 2008-11-06 | Zhiqiang Gao | Electrochemical Method of Detecting an Analyte |
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
CA2658023C (en) * | 2006-04-19 | 2012-01-10 | Panasonic Corporation | Biosensor |
MX2008014251A (en) | 2006-05-08 | 2008-11-26 | Bayer Healthcare Llc | Electrochemical test sensor with reduced sample volume. |
TW200813429A (en) * | 2006-09-01 | 2008-03-16 | Gen Life Biotechnology Co Ltd | Sensor for inspecting the total cholesterol in blood sample |
JP5044655B2 (en) * | 2006-10-05 | 2012-10-10 | ライフスキャン・スコットランド・リミテッド | Reagent formulations using ruthenium hexamine as a transmitter for electrochemical test strips |
US9046480B2 (en) | 2006-10-05 | 2015-06-02 | Lifescan Scotland Limited | Method for determining hematocrit corrected analyte concentrations |
EP2679150B1 (en) | 2006-10-24 | 2020-07-22 | Ascensia Diabetes Care Holdings AG | Transient decay amperometry |
EP1964927A1 (en) | 2007-02-27 | 2008-09-03 | F. Hoffmann-La Roche AG | Quinones as mediators for photometric tests |
JP5219022B2 (en) * | 2007-06-15 | 2013-06-26 | 株式会社船井電機新応用技術研究所 | Enzyme electrode and enzyme sensor |
US8160900B2 (en) | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US8163146B2 (en) * | 2007-10-12 | 2012-04-24 | Abbott Diabetes Care Inc. | Mediator stabilized reagent compositions for use in biosensor electrodes |
WO2009076271A2 (en) * | 2007-12-10 | 2009-06-18 | Bayer Healthcare Llc | Wear-resistant electrochemical test sensor and method of forming the same |
WO2009076302A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Healthcare Llc | Control markers for auto-detection of control solution and methods of use |
USD612279S1 (en) | 2008-01-18 | 2010-03-23 | Lifescan Scotland Limited | User interface in an analyte meter |
IL197532A0 (en) * | 2008-03-21 | 2009-12-24 | Lifescan Scotland Ltd | Analyte testing method and system |
US8262874B2 (en) * | 2008-04-14 | 2012-09-11 | Abbott Diabetes Care Inc. | Biosensor coating composition and methods thereof |
US20090294302A1 (en) * | 2008-05-28 | 2009-12-03 | John Pasqua | Use of Alginate to Reduce Hematocrit Bias in Biosensors |
US8924159B2 (en) | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
JP5816080B2 (en) | 2008-05-30 | 2015-11-17 | インテュイティ メディカル インコーポレイテッド | Body fluid collection device and collection site interface |
US8591410B2 (en) | 2008-05-30 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
CA2726067C (en) | 2008-06-06 | 2020-10-20 | Intuity Medical, Inc. | Detection meter and mode of operation |
USD611151S1 (en) | 2008-06-10 | 2010-03-02 | Lifescan Scotland, Ltd. | Test meter |
PL2313364T3 (en) | 2008-08-07 | 2021-03-08 | Idexx Laboratories, Inc. | Methods for detecting symmetrical demethylarginine |
USD611372S1 (en) | 2008-09-19 | 2010-03-09 | Lifescan Scotland Limited | Analyte test meter |
US20100213057A1 (en) | 2009-02-26 | 2010-08-26 | Benjamin Feldman | Self-Powered Analyte Sensor |
US20100270152A1 (en) * | 2009-04-24 | 2010-10-28 | Lifescan Scotland Limited | Enzymatic reagent ink |
KR20100117173A (en) * | 2009-04-24 | 2010-11-03 | 쓰리엠 이노베이티브 프로퍼티즈 캄파니 | Electrochemical biosensor electrode strip and preparing method thereof |
US8025788B2 (en) * | 2009-04-24 | 2011-09-27 | Lifescan Scotland Limited | Method for manufacturing an enzymatic reagent ink |
US20100273249A1 (en) * | 2009-04-24 | 2010-10-28 | Lifescan Scotland Limited | Analytical test strips |
US8359081B2 (en) * | 2009-04-28 | 2013-01-22 | Abbott Diabetes Care Inc. | Service-detectable analyte sensors and methods of using and making same |
CN103487476B (en) | 2009-05-25 | 2015-09-09 | 利多(香港)有限公司 | Biology sensor |
US8298158B2 (en) | 2009-06-30 | 2012-10-30 | Abbott Diabetes Care Inc. | Integrated devices having extruded electrode structures and methods of using same |
US8437827B2 (en) * | 2009-06-30 | 2013-05-07 | Abbott Diabetes Care Inc. | Extruded analyte sensors and methods of using same |
US20110046466A1 (en) * | 2009-08-19 | 2011-02-24 | Feldman Benjamin J | Analyte Sensors Including Nanomaterials and Methods of Using Same |
US8357276B2 (en) * | 2009-08-31 | 2013-01-22 | Abbott Diabetes Care Inc. | Small volume test strips with large sample fill ports, supported test strips, and methods of making and using same |
US20110124993A1 (en) * | 2009-11-24 | 2011-05-26 | Abbott Diabetes Care Inc. | Analyte Sensors Comprising Self-Polymerizing Hydrogels |
US9042954B2 (en) | 2009-11-24 | 2015-05-26 | Abbott Diabetes Care Inc. | Analyte sensors comprising hydrogel membranes |
US8354013B2 (en) | 2009-11-24 | 2013-01-15 | Abbott Diabetes Care Inc. | Analyte sensors comprising high-boiling point solvents |
US8919605B2 (en) | 2009-11-30 | 2014-12-30 | Intuity Medical, Inc. | Calibration material delivery devices and methods |
US8726266B2 (en) | 2010-05-24 | 2014-05-13 | Abbott Diabetes Care Inc. | Method and system for updating a medical device |
EP2598021B1 (en) | 2010-07-28 | 2015-08-19 | Abbott Diabetes Care, Inc. | Analyte sensors having temperature independent membranes |
AU2011338255B2 (en) | 2010-12-09 | 2016-06-02 | Abbott Diabetes Care Inc. | Analyte sensors with a sensing surface having small sensing spots |
CA3177983A1 (en) | 2011-02-28 | 2012-11-15 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US9380965B2 (en) | 2011-05-20 | 2016-07-05 | Abbott Diabetes Care Inc. | Analyte sensors having a membrane with low temperature sensitivity |
EP3973859A1 (en) | 2011-06-17 | 2022-03-30 | Abbott Diabetes Care, Inc. | Connectors for making connections between analyte sensors and other devices |
WO2013020103A1 (en) | 2011-08-03 | 2013-02-07 | Intuity Medical, Inc. | Devices and methods for body fluid sampling and analysis |
CN104023968B (en) * | 2011-12-22 | 2017-05-24 | 帝斯曼知识产权资产管理有限公司 | Multilayered woven manufacture and use of the multilayer woven manufacture as carriers for dried matrix spot applications |
KR101466222B1 (en) | 2012-06-01 | 2014-12-01 | 주식회사 아이센스 | Electrochemical biosensor with improved accuracy |
US9535027B2 (en) | 2012-07-25 | 2017-01-03 | Abbott Diabetes Care Inc. | Analyte sensors and methods of using same |
US10004439B2 (en) | 2012-09-21 | 2018-06-26 | Abbott Diabetes Care Inc. | In vivo sensors having ceria nanoparticle electrodes |
US8921061B2 (en) | 2012-11-02 | 2014-12-30 | Roche Diagnostics Operations, Inc. | Reagent materials and associated test elements |
US8920628B2 (en) | 2012-11-02 | 2014-12-30 | Roche Diagnostics Operations, Inc. | Systems and methods for multiple analyte analysis |
CN102998351B (en) * | 2012-12-12 | 2015-04-15 | 广州东林生物科技有限公司 | Auxiliary reagent for ISE module of biochemical analyzer |
WO2014100423A1 (en) | 2012-12-21 | 2014-06-26 | Abbott Diabetes Care Inc. | Method for improving measurement accuracy and devices and systems related thereto |
CN105377118B (en) | 2013-03-15 | 2019-09-17 | 雅培糖尿病护理公司 | Equipment, system and method associated with analyte supervision equipment and the equipment comprising it |
WO2014179343A1 (en) | 2013-04-30 | 2014-11-06 | Abbott Diabetes Care Inc. | Systems, devices, and methods for energy efficient electrical device activation |
JP6657096B2 (en) | 2013-09-05 | 2020-03-04 | アイデックス ラボラトリーズ インコーポレイテッドIDEXX Laboratories, Inc. | Methods for detecting kidney disease |
EP3087771B1 (en) | 2013-12-27 | 2020-06-17 | Abbott Diabetes Care, Inc. | Systems, devices, and methods for authentication in an analyte monitoring environment |
DE202014010579U1 (en) | 2013-12-27 | 2016-01-05 | Abbott Diabetes Care Inc. | Application interface and display control in an analyte monitoring environment |
JP2015155841A (en) * | 2014-02-20 | 2015-08-27 | 株式会社村田製作所 | biosensor |
EP3624475B1 (en) | 2014-05-21 | 2024-03-20 | Abbott Diabetes Care, Inc. | Management of multiple devices within an analyte monitoring environment |
CA2957676A1 (en) | 2014-08-15 | 2016-02-18 | Abbott Diabetes Care Inc. | Temperature insensitive in vivo analyte devices, methods and systems |
EP4170346A1 (en) | 2015-02-20 | 2023-04-26 | Idexx Laboratories, Inc. | Homogenous immunoassay with compensation for background signal |
EP3307164B1 (en) | 2015-06-15 | 2021-05-12 | Abbott Diabetes Care Inc. | Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same |
US10888272B2 (en) | 2015-07-10 | 2021-01-12 | Abbott Diabetes Care Inc. | Systems, devices, and methods for meal information collection, meal assessment, and analyte data correlation |
CN104931560A (en) * | 2015-07-17 | 2015-09-23 | 王天星 | Biosensor and preparation method and application thereof |
US11091788B2 (en) | 2016-03-04 | 2021-08-17 | Abbott Diabetes Care Inc. | NAD(P)- dependent responsive enzymes, electrodes and sensors, and methods for making and using the same |
DK3668400T3 (en) | 2017-08-18 | 2023-09-18 | Abbott Diabetes Care Inc | Method for individualized calibration of analyte sensors |
US11422136B2 (en) | 2017-10-19 | 2022-08-23 | Idexx Laboratories, Inc. | Detection of symmetrical dimethylarginine |
WO2019152966A1 (en) | 2018-02-05 | 2019-08-08 | Abbott Diabetes Care Inc. | Notes and event log information associated with analyte sensors |
US20190320947A1 (en) | 2018-04-19 | 2019-10-24 | Abbott Diabetes Care Inc. | Lactate sensors and associated methods |
US20210236028A1 (en) | 2018-05-17 | 2021-08-05 | Abbott Diabetes Care Inc. | Analyte sensor antimicrobial configurations and adhesives |
CN109001293B (en) * | 2018-08-16 | 2020-01-17 | 中国地质大学(武汉) | In-situ osmium isotope testing method with high sensitivity and high spatial resolution |
AU2019427806B2 (en) | 2019-01-28 | 2023-06-01 | Abbott Diabetes Care Inc. | Analyte sensors and sensing methods for detecting creatinine |
JP7196315B2 (en) | 2019-01-28 | 2022-12-26 | アボット ダイアベティス ケア インコーポレイテッド | Analyte sensor and detection method featuring dual glucose and ketone detection |
US20200237276A1 (en) | 2019-01-28 | 2020-07-30 | Abbott Diabetes Care Inc. | Analyte sensors employing multiple enzymes and methods associated therewith |
WO2020159981A1 (en) | 2019-01-28 | 2020-08-06 | Abbott Diabetes Care Inc. | Analyte sensors and sensing methods for dual detection of glucose and ethanol |
EP4021301A1 (en) | 2019-08-30 | 2022-07-06 | Abbott Diabetes Care Inc. | Analyte sensors and sensing methods for the detection of alcohol |
WO2021042033A1 (en) * | 2019-08-31 | 2021-03-04 | PercuSense, Inc. | Analyte sensor |
CN110609070A (en) * | 2019-08-31 | 2019-12-24 | 广东工业大学 | Nanometer flower and application thereof in detecting glucose concentration |
WO2021067608A1 (en) | 2019-10-02 | 2021-04-08 | Abbott Laboratories | Detection of analytes by protein switches |
EP4081792A1 (en) | 2019-12-23 | 2022-11-02 | Abbott Diabetes Care Inc. | Analyte sensors and sensing methods featuring low-potential detection |
CN111239229B (en) * | 2020-02-24 | 2023-04-11 | 江苏鱼跃医疗设备股份有限公司 | Dual-channel electrochemical biosensor and method for measuring heme concentration |
US20210369155A1 (en) | 2020-05-29 | 2021-12-02 | Abbott Diabetes Care Inc. | Analyte Sensors and Sensing Methods for Detecting Inhibitors of Diaphorase |
CN116600710A (en) | 2020-06-10 | 2023-08-15 | 美国雅培糖尿病护理公司 | Analyte sensor with one or more detection-enhancing features |
USD957438S1 (en) | 2020-07-29 | 2022-07-12 | Abbott Diabetes Care Inc. | Display screen or portion thereof with graphical user interface |
WO2022125998A1 (en) | 2020-12-10 | 2022-06-16 | Abbott Diabetes Care Inc. | Analyte sensors for sensing ketones and methods of using the same |
CA3200244A1 (en) | 2020-12-15 | 2022-06-23 | Tianmei Ouyang | Nad(p) depot for nad(p)-dependent enzyme-based sensors |
EP4267752A1 (en) | 2020-12-23 | 2023-11-01 | Abbott Diabetes Care, Inc. | Analyte sensors for sensing glutamate and methods of using the same |
JP2024501294A (en) | 2020-12-23 | 2024-01-11 | アボット ダイアベティス ケア インコーポレイテッド | Continuous potassium sensor and how to use it |
CN117098852A (en) | 2020-12-30 | 2023-11-21 | 美国雅培糖尿病护理公司 | Analyte sensor for detecting asparagine and aspartic acid and methods of use thereof |
AU2022205042A1 (en) | 2020-12-31 | 2023-06-15 | Abbott Diabetes Care Inc. | An analyte sensor and sharp for delivering a therapeutic agent in close proximity to an analyte sensor and methods therefore |
US20220202327A1 (en) | 2020-12-31 | 2022-06-30 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use thereof |
CA3200886A1 (en) | 2020-12-31 | 2022-06-07 | Phu Le | Analyte sensors with metal-containing redox mediators and methods of using the same |
CA3205353A1 (en) | 2021-01-26 | 2022-08-04 | Shridhara A. Karinka | Systems, devices, and methods related to ketone sensors |
WO2024020007A1 (en) | 2022-07-19 | 2024-01-25 | Abbott Diabetes Care Inc. | Analyte sensors with reduced interferent signal and methods |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5147806A (en) * | 1988-04-29 | 1992-09-15 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescence measurements |
US5320725A (en) * | 1989-08-02 | 1994-06-14 | E. Heller & Company | Electrode and method for the detection of hydrogen peroxide |
US5264104A (en) * | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
JPH04278450A (en) * | 1991-03-04 | 1992-10-05 | Adam Heller | Biosensor and method for analyzing subject |
US5593852A (en) * | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
US5262305A (en) * | 1991-03-04 | 1993-11-16 | E. Heller & Company | Interferant eliminating biosensors |
EP0813608B1 (en) * | 1995-02-14 | 2002-09-04 | Roche Diagnostics Corporation | Osmium-containing redox mediator |
AUPN363995A0 (en) * | 1995-06-19 | 1995-07-13 | Memtec Limited | Electrochemical cell |
US5665222A (en) * | 1995-10-11 | 1997-09-09 | E. Heller & Company | Soybean peroxidase electrochemical sensor |
US5972199A (en) * | 1995-10-11 | 1999-10-26 | E. Heller & Company | Electrochemical analyte sensors using thermostable peroxidase |
US5708247A (en) * | 1996-02-14 | 1998-01-13 | Selfcare, Inc. | Disposable glucose test strips, and methods and compositions for making same |
WO1998035225A1 (en) | 1997-02-06 | 1998-08-13 | E. Heller & Company | Small volume in vitro analyte sensor |
US5948695A (en) * | 1997-06-17 | 1999-09-07 | Mercury Diagnostics, Inc. | Device for determination of an analyte in a body fluid |
CO5040209A1 (en) | 1997-10-16 | 2001-05-29 | Abbott Lab | BIOSENSOR ELECTRODES MEDIATORS OF COFACTOR REGENERATION |
US6736957B1 (en) * | 1997-10-16 | 2004-05-18 | Abbott Laboratories | Biosensor electrode mediators for regeneration of cofactors and process for using |
US6134461A (en) * | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
US6103033A (en) * | 1998-03-04 | 2000-08-15 | Therasense, Inc. | Process for producing an electrochemical biosensor |
US6175752B1 (en) * | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6338790B1 (en) * | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US6287451B1 (en) * | 1999-06-02 | 2001-09-11 | Handani Winarta | Disposable sensor and method of making |
DE60024965T2 (en) | 1999-10-05 | 2006-07-13 | Matsushita Electric Industrial Co., Ltd., Kadoma | GLUCOSE SENSOR |
JP2001159618A (en) * | 1999-12-03 | 2001-06-12 | Matsushita Electric Ind Co Ltd | Biosensor |
JP2001249103A (en) * | 1999-12-27 | 2001-09-14 | Matsushita Electric Ind Co Ltd | Biosensor |
JP4061816B2 (en) * | 2000-04-27 | 2008-03-19 | 松下電器産業株式会社 | Biosensor |
AU2001263022A1 (en) * | 2000-05-12 | 2001-11-26 | Therasense, Inc. | Electrodes with multilayer membranes and methods of using and making the electrodes |
JP4627912B2 (en) * | 2000-11-09 | 2011-02-09 | パナソニック株式会社 | Biosensor |
US7501053B2 (en) * | 2002-10-23 | 2009-03-10 | Abbott Laboratories | Biosensor having improved hematocrit and oxygen biases |
US20050067277A1 (en) * | 2003-09-30 | 2005-03-31 | Pierce Robin D. | Low volume electrochemical biosensor |
US8163146B2 (en) * | 2007-10-12 | 2012-04-24 | Abbott Diabetes Care Inc. | Mediator stabilized reagent compositions for use in biosensor electrodes |
US8262874B2 (en) * | 2008-04-14 | 2012-09-11 | Abbott Diabetes Care Inc. | Biosensor coating composition and methods thereof |
-
2002
- 2002-10-23 US US10/278,657 patent/US7501053B2/en active Active
-
2003
- 2003-10-22 CA CA002503086A patent/CA2503086A1/en not_active Abandoned
- 2003-10-22 JP JP2004547049A patent/JP4695879B2/en not_active Expired - Fee Related
- 2003-10-22 WO PCT/US2003/033532 patent/WO2004038401A2/en active Application Filing
- 2003-10-22 AU AU2003286597A patent/AU2003286597A1/en not_active Abandoned
- 2003-10-22 EP EP03777801A patent/EP1556689A2/en not_active Ceased
-
2006
- 2006-05-26 US US11/420,628 patent/US7754093B2/en active Active
-
2010
- 2010-06-14 US US12/815,169 patent/US8163160B2/en not_active Expired - Fee Related
-
2012
- 2012-04-02 US US13/437,695 patent/US20130001101A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20110031133A1 (en) | 2011-02-10 |
US7754093B2 (en) | 2010-07-13 |
US8163160B2 (en) | 2012-04-24 |
AU2003286597A8 (en) | 2004-05-13 |
US20060201805A1 (en) | 2006-09-14 |
US7501053B2 (en) | 2009-03-10 |
AU2003286597A1 (en) | 2004-05-13 |
WO2004038401A3 (en) | 2004-06-17 |
US20130001101A1 (en) | 2013-01-03 |
JP4695879B2 (en) | 2011-06-08 |
JP2006504096A (en) | 2006-02-02 |
WO2004038401A2 (en) | 2004-05-06 |
US20040079653A1 (en) | 2004-04-29 |
EP1556689A2 (en) | 2005-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7501053B2 (en) | Biosensor having improved hematocrit and oxygen biases | |
CA2470465C (en) | Improved biosensor and method | |
US6863800B2 (en) | Electrochemical biosensor strip for analysis of liquid samples | |
CA2481425C (en) | Disposable sensor with enhanced sample port inlet | |
KR100790141B1 (en) | Glucose biosensor and method | |
CA2402354C (en) | Rapid response glucose sensor | |
JP3965212B2 (en) | Electrochemical measurement of fructosamine | |
RU2450263C2 (en) | Biosensor system having high stability and hematocrit performance | |
US7611621B2 (en) | Disposable oxygen sensor and method for correcting oxygen effect on oxidase-based analytical devices | |
GB2351153A (en) | Electrochemical cell incorporating enzyme electrode | |
AU3835899A (en) | Test strip | |
CN104280431A (en) | Reagent composition for biosensor and biosensor having the same | |
Yao et al. | Simultaneous in vivo monitoring of glucose, L-lactate, and pyruvate concentrations in rat brain by a flow-injection biosensor system with an on-line microdialysis sampling | |
WO2001002827A9 (en) | Biosensor | |
Dock et al. | Effect of interfering substances on current response of recombinant peroxidase and glucose oxidase–recombinant peroxidase modified graphite electrodes | |
KR20230150262A (en) | Disposable electrochemical biosensor based on NAD(P)-dependent dehydrogenase and diaphorase | |
AU2006209265A1 (en) | Rapid response glucose sensor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |